Cite
HARVARD Citation
Zhang, Y. et al. (2022). Combination of PD‐1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second‐line therapy for relapsed/refractory classical Hodgkin lymphoma. British journal of haematology. pp. 127-135. [Online].